October 24, 2017October 24, 2017

Immune Design’s G100 Receives EMA’s Orphan Drug Designation for Follicular Non-Hodgkin’s Lymphoma

News

The European Medicines Agency (EMA) has granted G100 orphan drug status for the treatment of follicular non-Hodgkin’s lymphoma, Immune Design, the drug’s developer, announced in a press release. The EMA orphan drug designation – ... Read more

April 4, 2016May 13, 2016

EMA Agrees to Consider Opdivo (nivolumab) as a Possible Treatment for Classical Hodgkin’s Lymphoma

News

Bristol-Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application of Opdivo (nivolumab), which seeks to extend Opdivo’s current indications to include the treatment of classical Hodgkin’s lymphoma (cHL) patients after prior therapies. The ... Read more